Elanco Animal Health Inc (ELAN) Shares Fall 3.8% -- What GF Scor
Elanco Animal Health Inc (ELAN) shares fell 3.8% to $23.56, indicating a 41.4% overvaluation according to the GF Value™ of $16.66. Despite an overall GF Score™ of 68/100 and strong momentum, the company faces challenges with financial strength and profitability. Notably, insiders have purchased $1.7 million in shares over the past year, suggesting confidence in its future.
245,707 Shares in Elanco Animal Health Incorporated $ELAN Purchased by Great Lakes Advisors LLC
Great Lakes Advisors LLC has purchased 245,707 shares of Elanco Animal Health Incorporated (NYSE:ELAN) valued at approximately $6.05 million. This acquisition is part of broader institutional interest, with 97.48% of the stock owned by institutional investors. Analysts maintain a "Moderate Buy" rating for Elanco, and the company recently exceeded quarterly earnings expectations, reporting $0.34 EPS on $1.37 billion in revenue.
Attention investors: You may be eligible for a $15 million Elanco Animal Health SEC fair fund payment
Investors who purchased Elanco Animal Health (NYSE: ELAN) common stock between May 9, 2019, and May 6, 2020, may be eligible for a payment from a $15 million SEC fair fund. The fund was established after Elanco paid a civil penalty for failing to disclose that quarter-end incentives to distributors boosted its reported revenue growth. Claims must be filed by September 14, 2026, and payments will be based on recognized losses calculated according to a specific plan of allocation.
Elanco Animal Health (NYSE:ELAN): Is More Momentum Ahead?
Elanco Animal Health (NYSE:ELAN) has shown improved operating results and raised its full-year revenue outlook, strengthening its recovery narrative. The company's future valuation hinges on sustained commercial execution, successful product launches, margin improvement, and financial discipline through portfolio changes. While recent momentum is positive, long-term uncertainties remain, requiring consistent execution to support growth and valuation expectations.
160,631 Shares in Elanco Animal Health Incorporated $ELAN Purchased by First National Bank of Omaha
First National Bank of Omaha recently acquired 160,631 shares of Elanco Animal Health (NYSE:ELAN) valued at approximately $3.97 million during the second quarter. This purchase contributes to institutional investors collectively owning 97.48% of ELAN's outstanding stock. Elanco exceeded quarterly earnings and revenue expectations, and analysts maintain a "Moderate Buy" rating with an average price target of $29.09.
Shiv O'neill Purchases 3,998 Shares of Elanco Animal Health (NYSE:ELAN) Stock
Insider Shiv O'neill recently purchased 3,998 shares of Elanco Animal Health (NYSE:ELAN) stock for $94,272.84, increasing direct ownership to 87,832 shares. This transaction follows Elanco's strong Q2 2026 earnings, where EPS and revenue exceeded analyst expectations. The company maintains a "Moderate Buy" consensus rating from analysts, with a target price of $29.09.
Elanco (NYSE: ELAN) legal chief buys 3,998 company shares
Elanco Animal Health Inc (ELAN) officer Shiv O'Neill, General Counsel and Corporate Secretary, purchased 3,998 shares of common stock on August 18, 2026, at $23.58 per share. This open-market transaction increased O'Neill's direct holdings to 87,832 shares. The purchase was not made under a Rule 10b5-1 trading plan.
S&CO Inc. Buys Shares of 111,284 Elanco Animal Health Incorporated $ELAN
S&CO Inc. recently acquired 111,284 shares of Elanco Animal Health Incorporated (NYSE:ELAN) for approximately $2.74 million, contributing to the 97.48% institutional ownership of the company. Elanco exceeded its Q2 earnings expectations, reporting an adjusted EPS of $0.34 and revenue of $1.37 billion, marking a 10.2% year-over-year increase. Analysts maintain a "Moderate Buy" rating for ELAN with an average price target of $29.09, and recent insider purchases by two directors further indicate confidence in the company's prospects.
Elanco Investors Fail to Revive Sales Misrepresentation Suit
The Seventh Circuit Court of Appeals has ruled against Elanco Animal Health Inc. investors, preventing them from proceeding with claims that the company misrepresented its sales. The court upheld the dismissal of the proposed class action, stating that the investors did not adequately allege fraudulent intent regarding the company's distribution practices. The ruling also touched upon violations of Sections 11 and 12(a) of the Securities Act of 1933, aligning with a majority of appeals courts on the interpretation of stricter federal requirements.
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN) and ACADIA Pharmaceuticals (ACAD)
J.P. Morgan analyst Chris Schott maintained a Buy rating on Elanco Animal Health (ELAN) with a consensus price target of $31.11, representing a 35.3% upside. Needham analyst Ami Fadia assigned a Buy rating to ACADIA Pharmaceuticals (ACAD) with a price target of $41.00, implying a 16.0% upside. Both companies are seen favorably within the Healthcare sector by these analysts.
Elanco Animal Health (ELAN) director purchases 5,000 shares of stock
Elanco Animal Health Inc. director Michael J. Harrington purchased 5,000 shares of common stock at $21.82 per share on August 12, 2026, increasing his direct holdings to 131,451 shares. This transaction, categorized as a positive "Filing Impact (Moderate)," was an open market or private transaction and not made under a Rule 10b5-1 trading plan. The purchase totals approximately $109,000.
Elanco Animal Health expands US screwworm response
Elanco Animal Health president and CEO Jeff Simmons discusses the company's efforts to combat the screwworm outbreak in the United States. The discussion took place on 'The Claman Countdown', highlighting Elanco's expanded response to the health issue.
Insider Buying: Elanco Animal Health (NYSE:ELAN) Director Buys 10,000 Shares of Stock
Elanco Animal Health (NYSE:ELAN) Director Paul Herendeen recently purchased 10,000 shares of the company's stock for $236,800, increasing his total ownership to 111,687 shares. This insider buying follows Elanco's strong quarterly earnings report, where the company beat estimates with $0.34 EPS and saw revenue increase by 10.2% year-over-year to $1.37 billion. Analysts currently hold a "Moderate Buy" consensus rating for ELAN, with an average price target of $29.09.
Insider Buying: Elanco Animal Health (NYSE:ELAN) CFO Buys $96,936.00 in Stock
Elanco Animal Health's CFO, Robert Vanhimbergen, purchased 4,200 shares of the company's stock for $96,936, increasing his holdings by 3.15%. This insider buying follows Elanco's strong quarterly results, which exceeded EPS and revenue expectations. Analysts maintain a "Moderate Buy" rating for ELAN with a consensus price target of $29.09.
Elanco Animal Health (NYSE: ELAN) director buys 10,000 shares at $23.69
Elanco Animal Health Inc. director Paul Herendeen reported an open-market purchase of 10,000 shares of common stock on August 7, 2026, at a price of $23.685 per share. This transaction increased his direct ownership to 111,687 shares. The Form 4 filing indicates a positive sentiment regarding the insider trade, as it was a purchase not made under a Rule 10b5-1 trading plan.
Bank of America Corp DE Has $80.36 Million Stake in Elanco Animal Health Incorporated $ELAN
Bank of America Corp DE significantly increased its stake in Elanco Animal Health Incorporated by 38% in Q1, bringing its total holding to $80.36 million. This comes as Elanco reported strong quarterly earnings, beating analyst expectations, and issued positive full-year EPS guidance. Analysts maintain a "Moderate Buy" rating, and company insiders have also recently purchased shares, indicating confidence in the stock.
Elanco Animal Health Number of Employees 2026 | Employee Count & Headcount Data
Elanco Animal Health (ELAN) had approximately 10,025 employees worldwide as of March 2026, marking a 2.8% growth since 2023. The company is actively hiring, with 772 job postings in 2026, a 40.1% increase from 2025. Its workforce is primarily concentrated in North America, and the average salary globally is $70,973.
Does Elanco (ELAN) Have a Durable Edge in Animal Health After Its Screwworm EUA Win?
Elanco Animal Health (ELAN) reported stronger Q2 sales and net income, along with an FDA Emergency Use Authorization for its CLiK Extra screwworm-prevention spray. The company also raised its full-year revenue guidance, positioning it as a key player in addressing the New World screwworm threat. This article examines how these developments may impact Elanco's investment narrative, emphasizing the importance of innovation and new product launches for sustained growth.
elanco animal health inc. Positive Earnings Pre-Announcements
Elanco Animal Health Inc. has pre-announced positive earnings, revising its FY26 estimated revenue range upwards from $5.010-$5.085 billion to $5.090-$5.140 billion. This follows recent news of the company boosting its FY26 outlook and experiencing a rise in Q2 income. The article also provides a timeline of other news related to Elanco, including product approvals and past earnings reports.
Elanco Animal Health Q2 Earnings Call Highlights
Elanco Animal Health reported strong second-quarter 2026 results, exceeding prior guidance with revenue up 10% to $1.368 billion, driven by new pet-health products like Zenrelia and Credelio Quattro, and growth in U.S. farm animal operations. The company raised its full-year organic constant-currency revenue growth outlook to 6% to 7% and improved its net leverage target. Innovation in both pet and farm animal segments, alongside productivity initiatives, are key drivers for Elanco's sustained growth.
Elanco Animal Health Incorporated (NYSE:ELAN) Receives Average Recommendation of "Moderate Buy" from Brokerages
Elanco Animal Health (NYSE:ELAN) has received a "Moderate Buy" consensus rating from analysts, with an average 12-month price target of $29.09, significantly above its current share price of $22.06. The company recently surpassed quarterly earnings expectations, reporting adjusted EPS of $0.34 on revenues of $1.37 billion, and provided positive guidance for Q3 and full-year 2026 EPS. Insider purchases by CEO Jeffrey N. Simmons and Rajeev A. Modi, alongside 97.48% institutional ownership, highlight confidence in the stock.
Elanco Animal Health Q2 Earnings Call Highlights
Elanco Animal Health reported strong Q2 2026 earnings, exceeding guidance with revenue up 10% year-over-year and adjusted EPS increasing 31%. Growth was primarily driven by pet health products like Zenrelia and Credelio Quattro, leading the company to raise its full-year outlook for organic constant-currency revenue growth. Elanco also reduced its net debt and improved its year-end net leverage target.
elanco animal health inc. Positive Earnings Pre-Announcements
Elanco Animal Health Inc. (ELAN) has pre-announced positive earnings for FY26, with an updated estimated range of $5.090-$5.140 Billion, up from $5.010-$5.085 Billion. This follows a recent boost in their FY26 outlook and a 7% stock increase reported on August 5, 2026. The company also announced a rise in Q2 income and USDA approval for a new product.
Elanco Ends Lobbying Relationship With Stumptown Strategies
Elanco Animal Health Inc. has terminated its lobbying contract with Stumptown Strategies LLC, a firm it paid approximately $10,000 per quarter. The company, which had Blair Larkins as its primary lobbyist, has been advocating for the Innovative FEED Act, legislation aimed at reclassifying certain animal feed substances as food additives rather than animal drugs.
Elanco Animal Health Inc (ELAN) Shares Fall 7.7% -- What GF Score of 66 Tells Investors
Elanco Animal Health Inc (ELAN) shares recently fell 7.7% to $24.20, making it 8.5% down for the week. The stock is currently deemed significantly overvalued with a GF Value™ of $15.62, despite having an above-average GF Score™ of 66/100. While insider activity shows purchases, suggesting some confidence, the company's unprofitability and negative cash flow raise concerns about its valuation and sustainability for investors.
Elanco raises 2026 outlook after strong second-quarter results
Elanco Animal Health Inc. reported a 10% increase in second-quarter revenue to $1.37 billion, leading the company to raise its full-year financial guidance for the second time. The growth was attributed to strong performance of new products like Zenrelia and Credelio Quattro, as well as significant increases in Pet Health and Farm Animal segments. Elanco now expects full-year revenue between $5.09 billion and $5.14 billion and has also increased its adjusted EBITDA and EPS targets.
UBS Adjusts Price Target on Elanco Animal Health to $33 From $31, Maintains Buy Rating
UBS has increased its price target for Elanco Animal Health to $33 from $31, while reiterating a Buy rating on the stock. This adjustment follows Elanco's Q2 2026 earnings call, where the company reported rising adjusted earnings and revenue and lifted its 2026 outlook. Elanco Animal Health is an animal health company focused on preventing and treating diseases in both farm animals and pets.
Elanco Animal Health (ELAN) Stock Eyes Margin Momentum As Debt Questions Linger
Elanco Animal Health's stock rose 2.4% following its Q2 2026 report, which showed significant improvement in adjusted EBITDA and gross margin, despite trailing losses. The company's "Big 6" portfolio and new products like Zenrelia and Credelio Quattro are driving revenue growth and market penetration. While progress in margin and debt reduction is evident, concerns remain about the sustainability of profitability and the company's leveraged balance sheet.
Elanco Animal Health posts Q2 2026 revenue $1.37B, raises full‑year guidance and improves net leverage
Elanco Animal Health reported strong second-quarter 2026 results, achieving $1.368 billion in revenue, a 10% year-over-year increase, and raising its full-year guidance for revenue, adjusted EBITDA, and adjusted EPS. The company also improved its year-end net leverage target and saw significant contributions from products like Zenrelia and Credelio Quattro. Elanco continues its Ascend productivity initiatives aimed at substantial adjusted EBITDA net savings by 2030, driven by faster-than-expected margin expansion.
Elanco Animal Health (NYSE:ELAN) Hits New 1-Year High Following Strong Earnings
Elanco Animal Health (NYSE:ELAN) shares reached a new 52-week high after reporting strong quarterly earnings of $0.34 EPS, surpassing estimates, with revenue rising 10.2% to $1.37 billion. The company provided Q3 and full-year 2026 EPS guidance, and analysts maintain a "Moderate Buy" rating with an average price target of $28.73. Insider purchases by CEO Jeffrey N. Simmons and Rajeev A. Modi, along with significant institutional ownership, highlight confidence in the company.
Press Release: Elanco Animal Health Reports Second Quarter 2026 Results
Elanco Animal Health (ELAN) has reported its second-quarter 2026 results. The article also briefly mentions Unity Software (U.US) which reported fourth-quarter revenue of $609 million, exceeding estimates, despite a quarterly loss of 66 cents per share. Full details of the Elanco report are behind a login wall due to copyright.
(ELAN) Elanco Animal Health Expects 2026 Revenue Range $5.09B - $5.14B, vs. FactSet Est of $5.07B
Elanco Animal Health (ELAN) announced its revenue expectations for 2026, forecasting a range of $5.09 billion to $5.14 billion. This projection surpasses the current FactSet estimate of $5.07 billion. The company also reported Q2 adjusted earnings and revenue increases, leading to an updated 2026 outlook.
(ELAN) Elanco Animal Health Incorporated Expects Q3 Revenue Range $1.20B - $1.22B
Elanco Animal Health Incorporated (ELAN) announced its Q3 revenue expectations, projecting a range of $1.20 billion to $1.22 billion. This follows their Q2 adjusted earnings and revenue rise, which led to an increase in their 2026 outlook, with revenue expected between $5.09 billion and $5.14 billion and adjusted EPS between $1.10 and $1.16. The company reported Q2 revenue of $1.37 billion and adjusted EPS of $0.34, surpassing FactSet estimates.
Elanco’s (NYSE:ELAN) Q2 CY2026: Strong Sales, Stock Soars
Elanco (NYSE: ELAN) reported stronger-than-expected Q2 CY2026 results, with revenue of $1.37 billion, a 10.2% year-on-year increase, and non-GAAP EPS of $0.34, significantly beating analyst estimates. The animal health company also raised its full-year revenue and adjusted EPS guidance, indicating positive momentum in the industry. Following these results, Elanco's stock rose by 6.2% to $27.16.
Elanco Animal Health Reports Second Quarter 2026 Results
Elanco Animal Health reported strong second-quarter 2026 results, with revenue up 10% year-over-year to $1,368 million and organic constant currency growth of 8%. The company raised its full-year 2026 outlook for revenue, adjusted EBITDA, and adjusted EPS, driven by successful new product launches like Zenrelia and Credelio Quattro. Elanco also improved its year-end net leverage ratio target to approximately 3.0x Adjusted EBITDA, reflecting strong financial performance and strategic execution.
Elanco raises 2026 outlook after Q2 revenue climbs 10%
Elanco Animal Health (ELAN) reported strong Q2 2026 results with revenue up 10% year over year to $1.368 billion, and net income rising significantly. Following this performance, the company has raised its full-year 2026 financial outlook, including revenue and adjusted EPS guidance, and increased its innovation revenue target. Insider trading activity shows purchases by executives, while institutional investors show mixed movements in their holdings.
Elanco Q2 2026 earnings: Innovation demand lifts revenue and margins
Elanco Animal Health reported strong Q2 2026 earnings, with revenue up 10% to $1.368 billion and GAAP EPS rising significantly due to demand for innovative pet health products and global ruminant portfolio growth. The company raised its full-year guidance for revenue, adjusted EBITDA, and adjusted EPS, reflecting improved profitability and cash flow, while also reducing its net leverage. Despite increased operational spending, a favorable product mix and pricing strategy contributed to margin expansion, with management highlighting Zenrelia and Credelio Quattro as key growth drivers.
Elanco Animal Health Incorporated (ELAN) Q2 Earnings and Revenues Beat Estimates
Elanco Animal Health (ELAN) reported strong Q2 2026 earnings, beating analyst estimates for both EPS and revenue. The company posted earnings of $0.34 per share against an estimate of $0.27, and revenues of $1.37 billion, surpassing the $1.24 billion expectation. Despite this positive performance, the stock currently holds a Zacks Rank #3 (Hold), suggesting it is expected to perform in line with the market.
First Trust Advisors LP Cuts Holdings in Elanco Animal Health Incorporated $ELAN
First Trust Advisors LP significantly reduced its stake in Elanco Animal Health Incorporated by 78.1% in the first quarter, selling 827,946 shares. Despite this, other institutional investors like PNC Financial Services Group Inc., KBC Group NV, and Swiss National Bank increased their holdings. Elanco Animal Health's stock is down 2.6%, with recent insider buying activity from its CEO and another insider, and analysts holding a "Moderate Buy" consensus rating.
California State Teachers Retirement System Increases Position in Elanco Animal Health Incorporated $ELAN
The California State Teachers Retirement System increased its stake in Elanco Animal Health (NYSE: ELAN) by 22.9% in the first quarter of 2026, bringing its total holdings to 576,936 shares valued at $13.8 million. Institutional investors now own 97.48% of the company's stock, while analysts maintain a "Moderate Buy" rating with an average price target of $28.73. Elanco recently surpassed quarterly expectations, reporting $0.40 in adjusted EPS on revenues of $1.37 billion, a 14.9% increase year-over-year.
Elanco Animal Health Incorporated $ELAN Shares Bought by Defilade Capital Management L.P.
Defilade Capital Management L.P. significantly increased its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 132.0% in the first quarter, now owning over 931,000 shares valued at $22.28 million. Other institutional investors also adjusted their positions, and insider activity shows CEO Jeffrey N. Simmons and insider Rajeev A. Modi acquiring shares in May. The company has a "Moderate Buy" consensus rating from analysts with an average price target of $28.73.
Elanco Releases 2025 Impact Report, Demonstrating How Animal Health Helps Meet Society's Growing Needs
Elanco Animal Health Inc. has released its "2025 Impact Report," detailing how the company's focus on innovation and purpose addresses societal challenges related to animal health
Elanco Releases 2025 Impact Report, Demonstrating How Animal Health Helps Meet Society's Growing Needs
Elanco Animal Health has released its 2025 Impact Report, "Leading with Purpose," detailing its progress in connecting purpose, innovation, and business strategy to address societal challenges. The report highlights achievements in animal health innovation, customer support, societal contributions, and employee engagement. Elanco aims to improve animal health, support farmers and veterinarians, strengthen the global food supply, and contribute to healthier communities.
Elanco Releases 2025 Impact Report, Demonstrating How Animal Health Helps Meet Society's Growing Needs
Elanco (NYSE: ELAN) has released its 2025 Impact Report, "Leading with Purpose," showcasing significant progress across animal health, customer support, societal contributions, and employee engagement. The report highlights $892 million in new innovation revenue, including the success of Zenrelia in treating over two million itchy dogs, and projects 5-6 new blockbuster approvals by 2031 with over $2 billion in potential peak sales. Elanco also details efforts in carbon reduction for cattle, global Salmonella control, and robust employee engagement and community support initiatives.
Arrowstreet Capital Limited Partnership Acquires 641,448 Shares of Elanco Animal Health Incorporated $ELAN
Arrowstreet Capital Limited Partnership significantly increased its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 310.0% in the first quarter, purchasing an additional 641,448 shares and bringing its total holdings to 848,372 shares valued at approximately $20.3 million. This move is part of broader institutional investment activity, with other hedge funds also adjusting their positions in Elanco. The company has a "Moderate Buy" consensus rating from analysts, with an average target price of $28.73, and recently reported strong quarterly earnings, beating estimates.
Elanco Animal Health Inc (ELAN) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis for Elanco Animal Health Inc (ELAN) as of July 29, 2026. The company has a current valuation score of 9.25, ranking 37th in the Pharmaceuticals industry, and its P/E ratio is -54.06. Key valuation metrics like P/B, P/S, and P/CF have not yet been disclosed by the company.
Elanco Animal Health (ELAN) Expected to Release Earnings on Wednesday
Elanco Animal Health (ELAN) is scheduled to release its Q2 2026 earnings before market open on Wednesday, August 5th. Analysts anticipate earnings of $0.28 per share and revenue of $1.3125 billion, aligning with the company's guidance of $0.250-$0.285 EPS. The company surpassed expectations in its previous quarter, reporting $0.40 EPS against a $0.34 consensus, with revenue up 14.9% year-over-year.
Elanco Animal Health Incorporated $ELAN is Redwood Grove Capital LLC's Largest Position
Redwood Grove Capital LLC maintains Elanco Animal Health Incorporated ($ELAN) as its largest position, despite reducing its stake by 17% in the first quarter, holding 1.29 million shares valued at approximately $30.9 million. This represents about 10% of Redwood Grove Capital's portfolio. Institutional ownership of Elanco is significant at 97.48%, with key insiders making notable share purchases in May, and analysts generally have a "Moderate Buy" rating with an average price target of $28.73, following the company's recent beat on quarterly earnings and revenue estimates.
Elanco Animal Health Incorporated (ELAN) Earnings Expected to Grow: Should You Buy?
Elanco Animal Health (ELAN) is expected to report a year-over-year increase in earnings and revenues for the quarter ended June 2026. The company has a Zacks Earnings ESP of +3.16% and a Zacks Rank #2 (Buy), suggesting a high probability of an earnings beat. Historically, Elanco has consistently surpassed EPS estimates in the last four quarters.
Elanco Animal Health (NYSE: ELAN) grants CFO deferred stock units
Elanco Animal Health's EVP and CFO, Robert M. VanHimbergen, was granted 7.9093 deferred stock units on July 24, 2026, priced at $24.91 per unit. These units represent a right to receive one share of common stock or the cash equivalent, settling upon employment termination or a specified future year under the Executive Deferral and Stock Match Plan. Following this grant, VanHimbergen holds a total of 124.6979 deferred stock units directly.
